AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04481841 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oryzanol + vitamin B2 (riboflavin) + vitamin E
Description: 1:Control group Specific medicines and usage, course of treatment are as follows: oryzanol + vitamin B2 (riboflavin) + vitamin E, oryzanol tablets, oral, 10 mg/time, 3 times/day; vitamin B2 tablets, oral, 10 mg/time, 3 times/day; vitamin E pills, oral, 100 mg/time, 1 time/day, 1 months as a course of treatment.~2.Therapeutic regimen of experimental group On the basis of classical Gu-Nucleus-E triple drug therapy, the experimental group was treated with head yuanshi dian therapy twice a day for 1 months as a course of treatment.
Study NCT05327712 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Control group
Description: No outreach during the intervention period beyond an initial eligibility notice.
Study NCT05327712 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Email only
Description: Email reminders in addition to an initial eligibility notice.
Study NCT05327712 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Phone only
Description: Phone call offering enrollment assistance in addition to an initial eligibility notice.
Study NCT05327712 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Phone and email
Description: Phone call and email reminders in addition to an initial eligibility notice.
Study NCT02464241 — intervention group
Intervention type: OTHER
Intervention: only examination
Study NCT02194140 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: oral iodinated contrast material
Description: diluted in water
Study NCT01433887 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 48-weeks course
Description: patients receive a dose of 180 µg of PEGASYS once a week for 48 weeks
Study NCT01433887 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: patients receive a dose 800 to 1200 mg of ribavirin once a day(according to weight) for 48 weeks
Study NCT01433887 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon alfa2a
Description: patients receive a dose of 180 µg of PEGASYS once a week for 24 weeks
Study NCT03283163 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Testing and Training
Description: The study group will perform a baseline maximum load exercise test which will inform the individualized exercise prescription for the participant. Based on a progressive methodology, the participant will engage in 12 weeks of exercise of their choice (walking, running, cycling or swimming) with the goal of working towards a maximum heart rate range of 80% between weeks 6 and 12 of the study.
Study NCT01351077 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CHICA DevScreen Module
Description: This module assists in the diagnosis and management of developmental screening
Study NCT02772887 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: L-Citrulline
Description: amino acid supplement
Study NCT02772887 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo
Study NCT03528707 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Symbiter-Omega
Description: Symbiter Omega which contains combination of flax and wheat germ oil (250 mg of each, concentration of omega-3 fatty acids 1-5%), supplemented with biomass of 14 alive probiotic strains: Lactobacillus + Lactococcus (6×1010 CFU/g), Bifidobacterium (1×101
Study NCT03528707 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Over 8 weeks of interventional period, the patient received 1 sachet (10 grams) of gel per day
Study NCT01433887 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: patients receive a dose 800 to 1200 mg of ribavirin once a day(according to weight) for 24 weeks
Study NCT03464201 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide 40 MG
Description: Enzalutamide 160 mg p.o. every day
Study NCT00035555 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belatacept
Description: Solution, intravenous
Study NCT00035555 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine
Description: Oral, capsule
Study NCT00035555 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF)
Description: Oral, capsule
Study NCT00035555 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Corticosteroids
Description: Corticosteroids given daily, orally or intravenously (IV). Day of transplant (Day 1): methylprednisolone, 500 mg, given IV on arrival in operating room; Day 2: methylprednisolone, 250 mg, given IV once daily; Day 3: prednisone, 100 mg, given orally once daily; Day 4: prednisone, 50 mg, given orally once daily; Days 5 through 30: prednisone, 25 mg, given orally once daily; Days 31-44: prednisone, 22.5 mg, given orally once daily; Days 45-58: prednisone, 20 mg, given orally once daily
Study NCT03690167 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Concentrated Growth Factor (CGF)
Description: CGF application (9 ml venous blood will harvested from the participants in the CGF group and centrifuged according to the protocol for CGF)
Study NCT03690167 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Advanced Platelet Rich Fibrin (A-PRF)
Description: A-PRF application (9 ml venous blood will harvested from the participants in the CGF group and centrifuged according to the protocol for A-PRF)
Study NCT03690167 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Control
Description: Nothing applied after extraction
Study NCT04234061 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: ibrutinib and Tisagenlecleucel
Description: Single-arm study investigating combination of ibrutinib and Tisagenlecleucel treatment
Study NCT00644189 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Clofarabine
Description: Taken orally once a day (in the AM) on days 1 through 21 of a 28-day cycle for a maximum of 6 cycles.
Study NCT00685750 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Collection of tumor and blood samples
Description: Samples will be collected before and after standard treatment
Study NCT03990987 — intervention group
Intervention type: OTHER
Intervention: time of receiving operation
Description: patients were randomly divided into Day group (D group) (8：00～12：00) and Night group (N group) (18：00～22：00), Patients received propofol, remifentanil, and DEX for general anesthesia maintenance
Study NCT05025631 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fruquintinib
Description: Fruquintinib was administered for 21 consecutive days of a 28-day treatment cycle. The starting dose of fruquintinib was 3 mg/day, weekly incremental dose escalation occurred up to the maximum of 5 mg/day if no significant drug-related toxicities were observed. The highest tolerated dose from cycle 1 would be administered in cycle 2 and all subsequent cycles.
Study NCT01485471 — intervention group
Intervention type: DEVICE
Intervention: Diffuse optical spectroscopy imaging
Description: ear exam imaging
Study NCT01142141 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: manual therapy, kinesiotherapy
Study NCT04048031 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Nutrafol Supplement Capsules
Description: NUTRAFOL's Synergen Complex Plus® is a formulation based on a patent-pending Synergen Complex®, a combination of botanicals with potent anti-inflammatory, anti-stress adaptogenic, antioxidant, DHT-inhibiting and hormone-rebalancing properties - combined to synergistically combat the multiple underlying factors that compromise hair growth and health. Some key ingredients include Sensoril Ashwagandha, BCM-95 BioCurcumin, Saw Palmetto, EVNolMax 20% Tocotrienol/Tocopherol complex, gelatinized Maca, Astaxanthin, Bioperine (piperine), and Capsimax (capsaicin), all of which are bio-optimized and clinically tested. The Nutafol supplement capsules are compared to the placebo capsules which contain no active ingredients. Four (4) capsules are taken by mouth once daily with a substantial meal.
Study NCT04048031 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Nutrafol Supplement Capsules
Description: NUTRAFOL's Synergen Complex Plus® is a formulation based on a patent-pending Synergen Complex®, a combination of botanicals with potent anti-inflammatory, anti-stress adaptogenic, antioxidant, DHT-inhibiting and hormone-rebalancing properties - combined to synergistically combat the multiple underlying factors that compromise hair growth and health. Some key ingredients include Sensoril Ashwagandha, BCM-95 BioCurcumin, Saw Palmetto, EVNolMax 20% Tocotrienol/Tocopherol complex, gelatinized Maca, Astaxanthin, Bioperine (piperine), and Capsimax (capsaicin), all of which are bio-optimized and clinically tested. The Nutafol supplement capsules are compared to the placebo capsules which contain no active ingredients. Four (4) capsules are taken by mouth once daily with a substantial meal.
Study NCT04048031 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Capsules
Description: The placebo capsules contain no active ingredients. Four (4) capsules are taken by mouth once daily with a substantial amount of food.
Study NCT03088033 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IASD System II implant
Description: The primary component of the system is an implant placed in the atrial septum designed to allow left to right flow between the left atrium and right atrium to reduce the elevated left atrial pressure.
Study NCT03088033 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: intra-cardiac echocardiography (ICE), or transesophageal echocardiography (TEE)
Description: intra-cardiac echocardiography (ICE), or transesophageal echocardiography (TEE) for examination of the atrial septum and left atrium.
Study NCT03213951 — intervention group
Intervention type: OTHER
Intervention: Experimental beta probe
Description: 3mCi (or similar) dose of 68Ga-PSMA-11 will be given prior to resection of cancer. Experimental beta probe designed to detect 68Ga-PSMA-11 will be used on prostate tissue after it has been surgically removed.
Study NCT03213951 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: PSMA-PET
Description: PSMA-PET imaging done prior to surgery and compared to whole mount imaging.
Study NCT01003327 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: I-gel
Description: intubation with I-gel airway
Study NCT01003327 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: LMA-Unique
Description: LMA-Unique airway is inserted first, then the I-gel
Study NCT02999659 — intervention group
Intervention type: DEVICE
Intervention: Pupilometer
Description: Device to measure change in pupil diameter due to a defined light stimulus.
Study NCT02928835 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Knee flexion Dynasplint orthosis
Description: Standardized rehabilitation procedures started at the first day after total knee arthroplasty. Both groups received the same standardized physical therapy intervention. The experimental group used the knee flexion Dynasplint orthosis (Dynasplint Systems, Inc. Canada, Woodbridge, ON) at night, while sleeping, over six continuous hours for one month, starting seven days after the total knee arthroplasty. The control group received only the standardized physical therapy intervention.
Study NCT03777020 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Service Dog Training Program
Description: Participate in 8 weekly dog training sessions using a positive reinforcement method and curriculum under the direct supervision of trainer at the Warrior Canine Connection facility in Boyds (Montgomery County) MD.
Study NCT03777020 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Dog Training Education
Description: Learn about training dogs by watching 8 weekly dog training online modules programs at the Warrior Canine Connection facility in Boyds (Montgomery County) MD. After completing this education the participants will participate in the service dog training program.
Study NCT03889535 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Resin strip crowns
Description: Technique:~I.Select shade of resin-based composite II.Rubber dam isolation III.Select primary incisor celluloid crown form with mesiodistal width similar to the tooth to be restored and trim the selected crown form to fit.~IV.Remove decay with slow speed round bur. Perform pulp therapy, if indicated. V.Reduce incisal edge by 1.5 mm VI.Reduce interproximal surfaces by 0.5 to 1.0 mm with feather edge at gingival margin. The interproximal walls should be approximately parallel.~VII.Reduce buccal surface by 1.0 mm and lingual surface by 0.5 mm with feather edge at gingival margins.~VIII. Round line angles IX.Etch for 15 to 20 seconds, rinse and air dry X. Apply bond and polymerise XI. Fill crown form to 2/3 full with composite resin and seat onto the tooth. Remove excess material with hand instrument. Polymerise.~XII. Remove celluloid crown form with scaler XIII. Finish and polish
Study NCT03889535 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Zirconia crowns
Description: I.Choose appropriately sized crown based on tooth's dimension; evaluate occlusion. II.Rubber dam isolation. III.Remove decay, perform pulp therapy if indicated. IV.Prep mesial half of incisal edge to complete thickness of 001 donut bur. V.Prep and blend distal half of incisal edge to create uniform incisal reduction. VI. Create chamfer margin at gum line at least half the thickness of bur tip. VII. Taper incisal half lingually to create a thin incisal edge. VIII. Remove cingulum and 0.75-1.25mm of lingual enamel; blend together forming smooth, slightly concave surface extending to tissue. IX. Thin incisal half. X.With 004 flame bur, remove chamfer margin at tissue level. Keep bur parallel to long axis of tooth. Remove chamfer in incremental steps, XI. Extend tip of bur full 2mm subgingivally. While hugging bur axially along root surface, make 3 circumferential passes. XII.Clean tooth and control bleeding. XIII.Cement crown with pure glass ionomer cement
Study NCT01805128 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Facial recognition of emotions
Description: The purpose is to consider the recognition of emotions expressed on face in patients with a schizophrenic disorder, autism and in healthy subjects.
Study NCT01805128 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: understanding metaphors
Description: Explore understanding of figurative language, including metaphor, in schizophrenic patients, autistic and healthy, and well understand how patients develop an interpretation from access to speaker's communicative intentionality (theory mind).
Study NCT01805128 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Attribution of intentionality to others in social situations depending on the type of situation
Description: Compare the style of attribution of intentions in three populations of subjects: schizophrenic, autistic and healthy.
Study NCT02291354 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pectin
Description: Patients allocated to experiment group will receive 12 g pectin each day for 12 weeks.
Study NCT02291354 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients allocated to experiment group will receive 12 g maltodextrin each day for 12 weeks.
Study NCT02291354 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fecal microbiota transplantation (FMT)
Description: Standardized Frozen Fecal Microbiota will be infused via nasointestinal tube.
Study NCT02291354 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Fecal microbiota transplantation (FMT)
Description: Standardized Frozen Fecal Microbiota will be infused via nasointestinal tube.
Study NCT04080440 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Extubation readiness clinical score
Description: After treatment of the acute neurological condition, eligibility for a spontaneous breathing trial will be assessed once a day.~In the intervention group, after a successful spontaneous breathing trial in unconscious patients, the score will be evaluated.~If the score is >9, extubation has to be completed
Study NCT04080440 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care
Description: After treatment of the acute neurological condition, eligibility for a spontaneous breathing trial will be assessed once a day.~In the control group, after a successful spontaneous breathing trial in unconscious patients, the extubation will be achieved according to the standard of care
Study NCT03664180 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bivalirudin
Description: IV infusion of 0.2 mg/kg/h (low-rate infusion) for at least 48h after the procedure or until discharge from CCU if it occurs later
Study NCT03664180 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enoxaparin
Description: 40mg/d s.c.for at least 48h after the procedure or until discharge from CCU if it occurs later
Study NCT03664180 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Unfractionated heparin
Description: IV infusion of 10 U/kg/h (maximum 1000 U) initially, adjusted to maintain ACT between 150 and 220 seconds for at least 48h after the procedure or until discharge from CCU if it occurs later
Study NCT03664180 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Bivalirudin placebo
Description: Matching placebo IV infusion for at least 48h after the procedure or until discharge from CCU if it occurs later
Study NCT03664180 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Enoxaparin placebo syringe
Description: Placebo syringe will be only prepared by a designated unblended medical professional on site. Placebo syringe will be presented in identical containers as a clear, colorless, sterile liquid of saline.Subcutaneous injection once a day for at least 48 hours after the procedure or until discharge from CCU if it occurs later.
Study NCT03664180 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Unfractionated heparin placebo
Description: Matching placebo IV infusion for at least 48h after the procedure or until discharge from CCU if it occurs later.
Study NCT04594239 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Belotero Balance (+) Lidocaine, needle
Description: Injection of Belotero Balance (+) Lidocaine to the infraorbital hollows using needles
Study NCT04594239 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Belotero Balance (+) Lidocaine, cannula
Description: Injection of Belotero Balance (+) Lidocaine into the infraorbital hollows using cannulas
Study NCT04594239 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Untreated-control / delayed-treatment, needle
Description: Untreated-control, followed by delayed-treatment with Belotero Balance (+) Lidocaine (injection of Belotero Balance (+) Lidocaine to the infraorbital hollows using needles)
Study NCT04594239 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Untreated-control / delayed-treatment, cannulas
Description: Untreated-control, followed by delayed-treatment with Belotero Balance (+) Lidocaine (injection of Belotero Balance (+) Lidocaine to the infraorbital hollows using cannulas)
Study NCT03445013 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SB414 6%
Description: Twice daily
Study NCT03445013 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: Vehicle Comparator
Study NCT02020577 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab( erbitux®)
Description: once per week
Study NCT02020577 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Afatinib
Description: once per day
Study NCT04098848 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cycling exercise
Description: Intradialytic cycling exercise for 30 minutes a time
Study NCT02058173 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 150 mg/daily chloroquine compare to placebo for 12 week
Study NCT02058173 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chloroquine
Study NCT02058173 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Study NCT01408264 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional 0.035 guidewire
Description: 0.035 guidewire
Study NCT01408264 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Olympus Visiglide 0.025 guidewire
Description: 0.025 guidewire
Study NCT02985437 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Surfactants
Study NCT02985437 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Saline Solution
Study NCT02643602 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hydration with bicarbonate in addition to theophylline
Description: 0.154-molar sodium bicarbonate; 3 ml per kg bodyweight (maximum 330 ml) one hour before contrast exposure; additionally 200 mg theophylline as a short infusion; after contrast application hydration with another 1 ml per kg bodyweight per hour (maximum 110 ml per hour) for 6 hours
Study NCT00653835 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ezetimibe + Simvastatin
Description: oral tablets: ezetimibe 10 mg + simvastatin 20 mg once daily for 6 weeks
Study NCT00653835 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Simvastatin
Description: oral tablets: simvastatin 20 mg + ezetimibe placebo once daily for 6 weeks
Study NCT02643602 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hydration with sodium chloride in addition to theophylline
Description: 0.9% sodium chloride; 3 ml per kg bodyweight (maximum 330 ml) one hour before contrast exposure; additionally 200 mg theophylline as a short infusion; after contrast application hydration with another 1 ml per kg bodyweight per hour (maximum 110 ml per hour) for 6 hours